Ryan McDonald | Authors


CLEAR Study Readout Shows Survival Enhancement With Lenvatinib Plus Pembrolizumab Versus Sunitinib in Frontline RCC

February 14, 2021

Better progression-free survival, as well as improved responses, were seen when lenvatinib was combined with either pembrolizumab or everolimus versus standard-of-care sunitinib in the treatment of patients with advanced renal cell carcinoma receiving therapy in the frontline setting.

Dual PD-1 and HER2 Blockade Plus Chemotherapy Proves Effective for Treatment of HER2+ Gastric, GEJ Cancer

January 15, 2021

Statistically significant improvements in median progression-free survival were observed in patients with HER2- amplified disease who were treated with pembrolizumab in combination with trastuzumab and cisplatin plus capecitabine compared with those without HER2-amplified disease.

Continued Ibrutinib Treatment Shows Similar 1-Year DFS in CLL/SLL

December 06, 2020

Following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

KTE-X19 Proves Comparable to Current Therapies in Treating High-Risk MCL

May 31, 2020

When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.

Cancer Progression Linked to Increased Risk of Death Within 30 Days of COVID-19 Diagnosis

May 28, 2020

Disease progression and treatment with hydroxychloroquine and azithromycin were associated with increased all-cause 30-day mortality in patients with cancer compared to patients either in remission or with no evidence of disease, according to data presented during a 2020 ASCO Virtual Scientific Program press briefing.